纳武单抗治疗晚期非小细胞肺癌的汇总分析及PD-L1作为预测生物标志物的作用。
A pooled analysis of nivolumab for the treatment of advanced non-small-cell lung cancer and the role of PD-L1 as a predictive biomarker.
作者信息
Aguiar Pedro N, Santoro Ilka Lopes, Tadokoro Hakaru, de Lima Lopes Gilberto, Filardi Bruno Andraus, Oliveira Pedro, Castelo-Branco Pedro, Mountzios Giannis, de Mello Ramon Andrade
机构信息
Division of Medical Oncology, Federal University of São Paulo, São Paulo, Brazil.
Department of Medical Oncology, Johns Hopkins University, Baltimore, MD 21218, USA.
出版信息
Immunotherapy. 2016 Sep;8(9):1011-9. doi: 10.2217/imt-2016-0032.
BACKGROUND
Recent studies with nivolumab (a monoclonal antibody against programmed cell death 1 [PD-1] receptor) have shown promise non-small-cell lung cancer (NSCLC) treatment.
METHODS
To review available clinical trials data in order to assess nivolumab efficacy and the role of tumoral PDL-1 expression as a biomarker.
RESULTS
Nine eligible studies included 2102 patients. In the second line setting, nivolumab achieved a 1-year survival rate of 41%; and in the first line, a 1-year survival rate of 76%. For those with PD-L1 expression <1%, nivolumab showed a trend for improved survival compared with docetaxel.
CONCLUSIONS
The available data reinforce nivolumab activity against NSCLC in first-line or subsequent lines. Although PD-L1 expression is related to greater response, PD-L1 negative patients had also some benefit.
背景
近期有关纳武单抗（一种抗程序性细胞死亡蛋白1[PD-1]受体的单克隆抗体）的研究显示其在非小细胞肺癌（NSCLC）治疗中具有前景。
方法
回顾现有临床试验数据，以评估纳武单抗的疗效以及肿瘤程序性死亡配体1（PDL-1）表达作为生物标志物的作用。
结果
9项符合条件的研究纳入了2102例患者。在二线治疗中，纳武单抗的1年生存率为41%；在一线治疗中，1年生存率为76%。对于PD-L1表达<1%的患者，与多西他赛相比，纳武单抗显示出改善生存的趋势。
结论
现有数据强化了纳武单抗在一线或后续治疗中对NSCLC的活性。尽管PD-L1表达与更高的反应相关，但PD-L1阴性的患者也有一定获益。
Zotero 插件